Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Janssen Biotech, the most common co-covered peer. At 5, the average consequence score sits below the same-window beat average of 5.9.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Core Molding Technologies
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Janssen Biotech, the most common co-covered peer. At 5, the average consequence score sits below the same-window beat average of 5.9. Source depth averages 2 original sources per story, versus 2.3 across the same-window beat baseline. Core Molding Technologies appears in 1 tracked Healthcare story from March 10, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 39 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Core Molding Technologies. Shared-story counts are live from our verified record — not editorial picks.
Legend Biotech (LEGN) has released its full-year 2025 financial results, showcasing significant revenue growth driven by the continued commercial expansion of its lead CAR-T therapy, Carvykti. The company highlighted major manufacturing milestones and a strategic pivot toward solid tumor indications following a year of intensive market penetration in earlier lines of multiple myeloma treatment.
